We previously implicated NCF1-NOX2-ROS in anti-tumor immunity [26], consistent with findings in CGD patients who exhibit reduced ROS production, TGFβ levels, and Treg frequencies [48,83]. The gene discussed is NCF1; the disease is neoplasm.